厄洛替尼二线治疗晚期非小细胞肺癌的临床观察被引量：2

Second-line therapy of erlotinib in advanced non-small cell lung cancer

在线阅读下载PDF

导出

摘要目的:观察厄洛替尼(特罗凯)单药二线治疗国人晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:28例晚期NSCLC患者口服厄洛替尼150mg/d治疗,连续服用2个月后,根据RECIST标准评价其近期疗效及NCI毒性评价标准评价不良反应。结果:28例患者中PR 5例(17.86%),SD 12例(42.86%),PD 11例(39.28%),有效率(CR+PR)为17.86%;疾病控制率(CR+PR+SD)为60.72%。肿瘤进展时间(TTP)为2～11个月,中位TTP为5.7个月;中位生存期(MST)为11.5个月。主要的毒副反应为皮疹、皮肤瘙痒、腹泻和恶心,多为Ⅰ～Ⅱ度,对症处理后可缓解。结论:厄洛替尼单药二线治疗国人晚期NSCLC疗效较好,且不良反应轻微。 Objective：To evaluate the efficacy and the side effect of erlotinib as the second line therapy in the treatment of patients with advanced non-small cell lung cancer（NSCLC）.Methods：Twenty-eight patients with advanced NSCLC were treated with erlotinib which was given orally as a single drug at a dose of 150mg per day.The efficacy was evaluated according to RECIST criteria and the adverse events were evaluated according to NCI criteria.Results：There was no complete response（CR）,partial response（PR） 17.86%,stable disease（SD） 42. 86% , progressive disease（PD） 39. 28%. The response rate（ CR ＋ PR） was 17.86% , the disease control rate（ CR ＋ PR ＋ SD） was 60. 72% in the 28 cases. Time to progression（TTP） was 2-11 months, and median time to progession （mTYP） was 5.7 months. Median survival time（MST） was 11.5 months. The main side effects were rash and itch of skin, diarrhea and nausea, which could be relieved by treatment. Conclusion：It is effective and feasible to treat advanced NSCLC with erlotinib as the second line therapy.

作者郝吉庆钱勇吴红阳

机构地区安徽医科大学第一附属医院肿瘤内科

出处《临床肿瘤学杂志》 CAS 2009年第8期701-703,共3页 Chinese Clinical Oncology

关键词非小细胞肺癌厄洛替尼靶向治疗 Non-small cell lung cancer（NSCLC） Erlotinib Target therapy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献5

1陆舜,李子明.肺癌靶向治疗——来自亚洲的数据[J].中国癌症杂志,2007,17(1):8-13. 被引量：26
2Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage Ⅳ non-small cell lung cancer [ J ]. Chest, 2003, 123(1Suppl) :226 -243.
3Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer [ J ]. N Engl J Med, 2005,353(2) :123 - 132.
4Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib : Quality of life analysis of the Natlonal Cancer Institute of Canada Clinical Trials Group Study BR.21[J]. J Clin Oncol, 2006, 24(24): 3831 -3837.
5Waeker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase Ⅲ studies[J]. Clin Cancer Res, 2007,13(13) : 3913 - 3921.